At a glance
ClinicalIndex Comparison RecordN/AUnknown· 100 target
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of Osimertinib in Patients With Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations
In Brief
An observational study for Advanced Non-Small Cell Lung Cancer. Targeting 100 participants across 1 site.
Detailed Summary
This is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. This study does not intend to intervene the current medical practice of the recruited patients.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Non-Small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
N/AUnknownOverdue
202120222023202420252026
Enrollment StartJan 2021
First PostedDec 2023
Primary CompletionJun 2025
Study CompletionSep 2025
TodayJul 2026
First PostedDec 18, 2023
Enrollment StartJan 1, 2021
Primary CompletionJun 15, 2025
Study CompletionSep 15, 2025
TodayJul 1, 2026
Enrollment to primary: 4.5 yearsPosted 2.5 years ago